Navigation Links
QRxPharma Announces MOXDUO License Deal In Israel

SYDNEY and BEDMINSTER, N.J., Nov. 27, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with ABIC Marketing Limited, the Israeli domestic subsidiary of Teva Pharmaceutical Industries Limited, for the commercialisation rights to immediate release MOXDUO in Israel.

"We are pleased to announce our strategic collaboration with Teva, the leading pharmaceutical marketing company in Israel and one of the largest in the world," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "The company's reputation, dedicated pain sales team and long-standing relationships with Israeli key opinion leaders will be an asset to the launch of MOXDUO in this market."

Under the licensing agreement, Teva will receive the exclusive rights to commercialise immediate release MOXDUO in Israel. Teva will assume responsibility for all regulatory and product launch costs as well as ongoing marketing and sales efforts. QRxPharma will receive an undisclosed up-front payment, regulatory and sales milestones, and double-digit royalties on the sales of immediate release MOXDUO in Israel. QRxPharma retains all rights to the intravenous and controlled release formulations of MOXDUO in the territory.

"Teva's interest in MOXDUO, together with that of Actavis, Paladin and Aspen, validate the need for safer opioids in the treatment of moderate to severe pain, and further endorse the commercial value of MOXDUO," added Holaday. "We are delighted to be working with such successful companies for the global commercialisation of immediate release MOXDUO."

QRxPharma will work with Teva to submit a marketing authorisation application to the Israeli health authority following approval of immediate release MOXDUO in the United States or Europe.

About QRxPharma
QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new pain management and abuse prevention products. Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risks and improved patient outcomes. The Company's New Drug Application for its lead product candidate immediate release MOXDUO® for the treatment of acute pain, was refiled with the US Food and Drug Administration in November 2013. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc., Aspen Group and Teva for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania), South Africa and Israel. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit

Forward Looking Statements 
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
2. QRxPharma Announces Collaboration With Aesica
3. QRxPharma Granted US Patent On Hybrid Opioids
4. QRxPharma Granted Additional US Patent on MoxDuo®
5. Elbit Imaging Announces the Results of the Companys Unsecured Financial Creditors Meeting Approving the General Terms of Agreement to be Entered Into With Bank Hapoalim
6. Net Health Announces New Vice President of Training and Implementation
7. Celsion Corporation Announces Strategic Loan Facility
8. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
9. China Nepstar Chain Drugstore Announces Annual Dividend
10. Veracyte, Inc. Announces Third Quarter 2013 Financial Results
11. Orexigen Announces Successful Interim Analysis of Contrave Light Study
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, ... of 750,000. The digital component is distributed nationally, through a vast social media ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa ... and Sepsis conditions present in similar ways and require time-critical intervention to avoid large ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
Breaking Medicine News(10 mins):